Grey Doyle is appointed CEO of Leading BioSciences Inc. Doyle, a long-standing member of Leading BioSciences’ executive management team and board of directors, previously served as chief operations officer and chief financial officer. Leading BioSciences is a clinical-stage biopharmaceutical company advancing a novel therapeutic that addresses the breakdown of the intestinal mucosal barrier.
Louis J. Vollmer is now president and CEO of Iroko Pharmaceuticals LLC. Vollmer has been serving as president of Iroko since March 2015 and continues as a member of Iroko’s board of directors, which he joined in February 2014. He succeeds Osagie Imasogie, Iroko’s founder, as CEO. Imasogie remains Iroko’s chairman. Iroko is a global specialty pharmaceutical company dedicated to scientific innovation in responsible pain management.
Douglas S. Boothe is now president of the Generics Division of Impax Laboratories Inc. Prior to Impax, Boothe served as executive VP and general manager, Perrigo Company Plc. Impax is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled release and specialty generics in addition to the development of central nervous system disorder branded products.
Jason Haddock was appointed chief financial officer of Array BioPharma. Haddock replaces David Horin, who had been acting as Array’s interim chief financial officer. Haddock most recently served as chief financial officer and chief operating officer of BERG Health. Array is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.
Lannett Company Inc. has named Kristie Stephens as VP of regulatory affairs and chief compliance officer. Additionally, John Kozlowski is now financial operations and corporate controller. Stephens served as Lannett’s director of regulatory affairs. Kozlowski most recently served as corporate controller. Lannett develops, manufactures, packages, markets, and distributes generic pharmaceutical products for a wide range of medical indications.
Karen Krumeich is now senior VP and chief financial officer of Soligenix Inc. Most recently, Krumeich served as a consultant providing finance, investor relations, and business development services to Soligenix and other healthcare companies. Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.
Kevin R. Lind has joined the management team of Arena Pharmaceuticals Inc. as executive VP and chief financial officer. Lind reports to Amit D. Munshi, Arena’s president and CEO. Prior to Arena, Lind was at TPG, most recently as a principal at TPG Special Situations Partners and initially at TPG-Axon’s Pharma Partners group. Arena is a biopharmaceutical company focused on discovering and developing novel, small molecule drugs.
Roy Eldor, M.D., Ph.D., has been appointed to the newly created position of chief medical director of Oramed Pharmaceuticals Inc. Dr. Eldor is an endocrinologist, internist, and researcher with more than 20 years of clinical and scientific experience. He is currently director of the Diabetes Unit at the Institute of Endocrinology, Metabolism & Hypertension, Tel-Aviv Sourasky Medical Center. Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection.
Mark A. Smith, M.D., Ph.D., has been appointed chief medical officer of VistaGen Therapeutics Inc. Prior to joining VistaGen, Dr. Smith served as the clinical lead for neuropsychiatry at Teva Pharmaceuticals. VistaGen Therapeutics is a clinical stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system.